Equities

Novo Integrated Sciences Inc

NVOS:NAQ

Novo Integrated Sciences Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.4774
  • Today's Change0.040 / 9.26%
  • Shares traded2.79m
  • 1 Year change-69.08%
  • Beta-0.7850
Data delayed at least 15 minutes, as of May 21 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novo Integrated Sciences, Inc. is a parent company to its subsidiaries. The Company owns Canadian and United States subsidiaries that provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutic, diagnostic solutions, personalized product offerings, and rehabilitative science. The Company operates through two segments: Healthcare Services and Product Sales. Its specialized multidisciplinary primary healthcare services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, dietician and others. Its subsidiaries include Novo Healthnet Limited, Novomerica Health Group, Inc., PRO-DIP, LLC and others.

  • Revenue in USD (TTM)13.66m
  • Net income in USD-12.08m
  • Incorporated2008
  • Employees127.00
  • Location
    Novo Integrated Sciences Inc11120 NE 2ND STREET, SUITE 100BELLEVUE 98004United StatesUSA
  • Phone+1 (206) 617-9797
  • Fax+1 (386) 943-6232
  • Websitehttps://www.novointegrated.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Greenbrook TMS Inc80.08m-68.03m4.25m629.00------0.053-2.21-2.212.48-1.061.07--6.67127,319.30-91.88-51.23-176.23-74.1544.9645.93-85.75-62.45---2.291.72--32.3938.06-149.38---22.47--
Assure Holdings Corp255.00k-21.45m4.32m95.00------16.96-3.80-4.600.055-2.280.0161--0.02722,684.21-135.04-35.15-937.78-46.37-860.3937.14-8,410.59-116.06---5.92-----45.86-55.626.19------
OpGen Inc3.07m-26.16m4.87m100.00--1.44--1.59-65.10-65.105.502.670.12022.915.6430,702.30-102.41-79.05-196.63-110.126.6222.60-852.12-706.290.1809-7.530.7746---39.45-4.0811.17--16.36--
Interpace Biosciences Inc40.66m1.25m6.00m108.004.89--3.030.14750.28020.20229.27-3.342.9014.328.37376,481.508.95-38.19---69.7359.0249.443.08-41.010.43553.11----26.3112.93118.96--0.9184--
Mangoceuticals Inc844.87k-9.02m6.28m--------7.43-0.492-0.4920.0455-0.04060.3826-------408.41---596.95--61.75---1,067.52--0.0622------8,082.22---361.07------
Selectis Health Inc36.67m-9.06m7.67m574.00------0.2091-2.96-2.9611.99-1.310.8309--15.6863,884.65-20.46-3.03-30.08-3.58-----24.63-4.84---3.361.12---9.4058.97-64.93---47.72--
Biocorrx Inc52.35k-3.99m7.69m5.00------146.90-0.464-0.4640.0061-1.210.102--0.9969---778.76-291.68----44.6467.13-7,635.86-3,208.40---3.49-----58.31-25.0413.79------
Novo Integrated Sciences Inc13.66m-12.08m8.32m127.00--0.3495--0.6095-0.7517-0.75170.85841.250.38248.708.88107,543.60-33.86-29.43-43.28-35.6440.3539.59-88.55-110.250.4089-3.980.1305--7.117.1759.77---22.73--
Syra Health Corp6.08m-3.60m8.54m78.00--2.55--1.40-0.5946-0.59461.050.52241.77--10.1977,937.56-105.01---154.43--23.75---59.21-----83.830.0279---1.83---38.72------
US NeuroSurgical Holdings Inc0.00-816.00k9.30m2.00--9.93-----0.0957-0.09570.000.06950.00----0.00-53.19-14.62-83.10-19.89-------36.77---15.000.00------38.97------
Pacific Health Care Organization Inc5.72m834.22k9.41m30.0011.290.855210.791.650.06510.06510.44590.85950.4725--6.09190,503.306.907.297.427.8179.4282.7514.6013.28----0.00---2.00-3.7055.80-10.80-15.93--
Medical Care Technologies Inc.0.00-1.07m9.47m0.00---------553,570.10-553,570.100.00-389.230.00-------154.94-----------------1.46---------40.06------
Caremax Inc810.36m-644.67m10.88m1.45k--0.5331--0.0134-172.31-172.31216.425.360.9467--6.07558,871.80-75.32---114.67---0.1988---79.55-----1.840.9506--19.01---1,707.99------
Univec Inc-100.00bn-100.00bn12.11m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Data as of May 21 2024. Currency figures normalised to Novo Integrated Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

4.65%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 2024291.92k1.53%
The Vanguard Group, Inc.as of 31 Mar 2024240.88k1.26%
Geode Capital Management LLCas of 31 Mar 2024127.93k0.67%
Virtu Americas LLCas of 31 Dec 202386.20k0.45%
XTX Markets LLCas of 31 Mar 202439.81k0.21%
SSgA Funds Management, Inc.as of 31 Mar 202433.28k0.18%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202427.91k0.15%
G1 Execution Services LLCas of 31 Mar 202417.85k0.09%
Tower Research Capital LLCas of 31 Mar 202411.06k0.06%
Vanguard Global Advisers LLCas of 31 Mar 20248.75k0.05%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.